These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 32770109)
1. Network-based modeling of drug effects on disease module in systemic sclerosis. Kim KJ; Moon SJ; Park KS; Tagkopoulos I Sci Rep; 2020 Aug; 10(1):13393. PubMed ID: 32770109 [TBL] [Abstract][Full Text] [Related]
3. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566 [TBL] [Abstract][Full Text] [Related]
5. Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis. Moon SJ; Bae JM; Park KS; Tagkopoulos I; Kim KJ Ann Rheum Dis; 2019 Jun; 78(6):817-825. PubMed ID: 30952646 [TBL] [Abstract][Full Text] [Related]
6. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. Distler O; Cozzio A Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237 [TBL] [Abstract][Full Text] [Related]
7. SSc in 2011: From mechanisms to medicines. Mouthon L Nat Rev Rheumatol; 2012 Jan; 8(2):72-4. PubMed ID: 22231235 [TBL] [Abstract][Full Text] [Related]
8. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940 [TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Distler JH; Distler O Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM; Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453 [TBL] [Abstract][Full Text] [Related]
12. Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods. Xu X; Ramanujam M; Visvanathan S; Assassi S; Liu Z; Li L PLoS One; 2020; 15(11):e0242863. PubMed ID: 33253326 [TBL] [Abstract][Full Text] [Related]
13. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib). Wermuth PJ; Jimenez SA PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973 [TBL] [Abstract][Full Text] [Related]
14. Integrated bulk and single-cell RNA-sequencing identified disease-relevant monocytes and a gene network module underlying systemic sclerosis. Kobayashi S; Nagafuchi Y; Okubo M; Sugimori Y; Shirai H; Hatano H; Junko M; Yanaoka H; Takeshima Y; Ota M; Iwasaki Y; Sumitomo S; Okamura T; Yamamoto K; Shoda H; Fujio K J Autoimmun; 2021 Jan; 116():102547. PubMed ID: 33039247 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Bournia VK; Evangelou K; Sfikakis PP Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. Liakouli V; Ciaffi J; Ursini F; Ruscitti P; Meliconi R; Ciccia F; Cipriani P; Giacomelli R Expert Rev Clin Immunol; 2020 Sep; 16(9):931-942. PubMed ID: 32893688 [TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235 [TBL] [Abstract][Full Text] [Related]